You are here: Industry Insights > M&A

News List

Takeda CEO gets his Shire megamerger, thanks to shareholder nod. Can he make it pay off? fiercepharma
December 06, 2018
Behold, Takeda can soon call itself a Big Pharma. Its shareholders joined Shire’s in separately approving the mega-M&A deal, despite opposition from a small group of dissidents...
Takeda could rack up $10B in selloffs after controversial Shire buyout: report fiercepharma
December 04, 2018
With a crucial shareholder vote looming, Takeda is on an aggressive push to win investor support for a Shire buyout expected to load the company with debt. Now, a top executive says that debt burden could be $10 billion lighter after the deal closes.
Bayer to cut loose animal health, consumer brands and 12,000 jobs in huge shakeup fiercepharma
December 04, 2018
At last, after back-and-forth speculation and denials, Bayer has revealed it will indeed cast off its animal health unit, a few consumer health brands and 12,000 jobs amid a large-scale restructuring that touches every area of its business.
GSK wraps up promised Horlicks sell-off in £3.1B deal with Unilever fiercepharma
December 04, 2018
After weighing options and offers for its Horlicks drinks brand in India for several months, GlaxoSmithKline signed off on a £3.1 billion sale to Unilever. The cash will help GSK cover the cost of its
Pharma shells out $100B on M&A in 2018 so far, with more to come fiercepharma
July 09, 2018
After an unusually slow 2017, deal-making in Big Pharma roared back to life in the first half of this year, with $100 billion spent on mergers and acquisitions so far.
Where do big-cap biopharmas stand on the M&A matrix? fiercepharma
May 30, 2018
Johnson & Johnson has the most bucks for biopharma M&A, Astellas the easiest target: analyst
Hazards of growth-by-M&A: Debt-laden Concordia tosses CEO, washes out investors in refi plan fiercepharma
May 07, 2018
Troubled Concordia, the Canadian drugmaker often compared to fellow price hiker Valeant, said on Thursday it had made a deal with creditors, replaced its CEO...
First-quarter acquisition activity lifts hopes for a big year EvaluatePharma
April 24, 2018
In the annals of biopharma M&A the first quarter of 2018 will go down as another strong start to the year, with $34bn in deals achieved without the benefit of a single mega-merger.
In Two Months, Biotech Startups Raised More Money Than In All Of 2013 forbes
March 13, 2018
If there are any worries about the future of biotech, don't tell the venture capitalists.
Healthcare M&A outlook bright for 2018: Analysts biospectrumasia
March 08, 2018
After a subdued 2017, analysts and industry experts predict 2018 to be a robust year for healthcare M&A

Previous page 1 2 3 4 5 6 Next page